tiprankstipranks

Exelixis backs FY25 revenue view of $2.15B-$2.25B, consensus $2.25B

“Exelixis (EXEL) is maintaining the previously provided financial guidance for fiscal year 2025. Net product and total revenues guidance do not currently reflect any revenues resulting from a potential U.S. regulatory approval and commercial launch of CABOMETYX for the treatment of patients with previously treated advanced neuroendocrine tumors. The U.S. Food and Drug Administration is currently reviewing Exelixis’ supplemental New Drug Application for this proposed indication, with a Prescription Drug User Fee Act – PDUFA – target action date of April 3,” the company stated.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue